Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A simple plan: chemotherapy-sparing approaches to early-stage and regional seminoma and nonseminoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Same author

Evaluation of ocular and systemic endpoints after radiation of posterior uveal melanoma - A systematic review and meta-analysis.

Heliyon·2024

Same author

Detection and size measurements of kidney stones on virtual non-contrast reconstructions derived from dual-layer computed tomography in an ex vivo phantom setup.

European radiology·2022

Same author

The current role of precision surgery in oligometastatic prostate cancer.

ESMO open·2022

Same author

Clinical characteristics, treatment patterns and relapse in patients with clinical stage IS testicular cancer.

World journal of urology·2021

Same author

[Influence of the working model on the education of young urologists : Education through the ages].

Der Urologe. Ausg. A·2021

Search research articles

Related Experiment Video

Updated: May 8, 2026

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

[Biomarker docetaxel-based chemotherapy].

D Pfister¹, A Heidenreich, D Porres

¹Klinik für Urologie, Universitätsklinikum Aachen, Pauwelsstraße 30, 52074, Aachen, Deutschland, dpfister@ukaachen.de.

Der Urologe. Ausg. A

|August 27, 2013

Summary

This summary is machine-generated.

Prostate cancer recurrence is common even with early detection. This review highlights key biomarkers and targets for advanced castration-resistant prostate cancer (CRPC) to improve treatment selection and patient outcomes.

More Related Videos

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers

Published on: February 20, 2017

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

Related Experiment Videos

Last Updated: May 8, 2026

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers

Published on: February 20, 2017

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

Area of Science:

Oncology
Biochemistry
Molecular Biology

Background:

Prostate cancer is often detected at local stages in the prostate-specific antigen (PSA) era.
Recurrent disease occurs in 10-40% of cases, necessitating further treatment.
Hormonal therapy can lead to castration-resistant prostate cancer (CRPC), where chemotherapy effectiveness is limited.

Purpose of the Study:

To review objective biomarkers, proteins, and molecular targets for CRPC.
To aid in selecting appropriate treatments for patients with advanced prostate cancer.
To discuss emerging drugs and prognostic markers in CRPC management.

Main Methods:

Literature review of prognostic molecular markers in prostate cancer.
Analysis of protein targets and biomarkers relevant to CRPC.
Discussion of recently approved and upcoming drugs for CRPC.

Main Results:

PSA sensitivity decreases in advanced stages of prostate cancer.
Chemotherapy benefits only about 50% of patients with CRPC.
Several new drugs and important molecular markers are emerging for CRPC treatment.

Conclusions:

Accurate identification of prognostic markers is crucial for effective CRPC treatment.
Biomarker-driven selection can improve chemotherapy response rates.
Ongoing research into novel targets and therapies is vital for advancing CRPC care.